Secondary Logo

C-106 Pan-neutralizing antibodies derived from human plasma targeting a new epitope

Sajadi, Mohammad, M.*,†; Dashti, Amir*; Pazgier, Marzena*; Tolbert, William, D.*; Seaman, Michael, S.; Ouyang, Xin*; Kim, Dongkyoon§; Cavet, Guy§; Redfield, Robert, R.*; Lewis, George, K.*; DeVico, Anthony, L.*

JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2018 - Volume 77 - Issue - p 39
doi: 10.1097/01.qai.0000532602.53717.4b
Abstracts: PDF Only
Free

Using a new methodology to obtain the sequences of antibodies in circulation, we have discovered a family of antibodies of remarkable breadth and potency: the N49 P series. Some members of this family have the capability to neutralize 100% of isolates tested in a Tier 1-3 multiclade 117 pseudovirus panel, including all pseudovirsuses that were resistant to other mAbs tested in the same panel (PGT121, GT 128, PGT 145, PGDM1400, PGT 151, 10-107 4, 10E8, PG9, PG16, 3BNC117, NIH 45-46, 8ANC195, VRC01, and VRC07). Elisa studies and sequence analysis show the N49 mAbs to have some characteristics of CD4-binding site antibodies. However, crystallographic studies show a bypassing of the CD4-binding site pocket in favor on the inner domain. The N49 P series has potential to be useful in passive immunization and prophylactic vaccine design for HIV-1.

*Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201

Department of Medicine, Baltimore VA Medical Center, Baltimore, MD 21201

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 3 Blackfan Circle, Boston, MA 02115

§Atreca, Inc., Redwood City, CA 94063

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.